Cost effects of a specialized care center for people with Alzheimer's disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 19, Issue 4, 2004, Pages 226-232

  Bloom, Bernard S ^a   Chhatre, Sumedha ^a   Jayadevappa, Ravi ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cost of Alzheimer's disease; Cost of dementia; Cost of illness; Economics

Indexed keywords

ADULT; AGED; ALZHEIMER DISEASE; ALZHEIMER DISEASE CENTER; AMBULATORY CARE; ARTICLE; CONTROLLED STUDY; COST OF ILLNESS; ETHNOLOGY; FEMALE; GENDER; HEALTH CARE COST; HEALTH CENTER; HOSPITALIZATION; HUMAN; INSTITUTIONAL CARE; INTERNAL MEDICINE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MEDICARE;

EID: 4143054669     PISSN: 15333175     EISSN: None     Source Type: Journal    
DOI: 10.1177/153331750401900406     Document Type: Article

References (27)

1. Brookmeyer R, Gray S, Kawas C: Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998; 88(9): 1337-1342.
2. Jorm AF, Korten AE, Henderson AS: The prevalence of dementia: A quantitative integration of the literature. Acta Psychiatr Scand. 1987; 76(5): 465-479.
3. Lobo A, Launer LJ, Fratiglioni L, et al.: Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurology. 2000; 54 (11 Suppl 5): S4-S9.
4. Ritchie K, Kildea D, Robine JM: The relationship between age and the prevalence of senile dementia: A meta-analysis of recent data. Int J Epidemiology. 1992; 21(4): 763-769.
5. Trabucchi M: An economic perspective on Alzheimer's disease. J Geriatr Psychiatry Neurol. 1999; 12(1): 29-38.
6. Ernst RL, Hay JW: Economic research on Alzheimer disease: A review of the literature. Alzheimer Dis Assoc Disord. 1997; 11(Suppl 6): 135-145.
7. Meek PD, McKeithan K, Schumock GT: Economic considerations in Alzheimer's disease. Pharmacotherapy. 1998; 18(2 Pt 2): 68-73.
8. Ernst RL, Hay JW: The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994; 84(8): 1261-1264.
9. Leon J, Cheng CK, Neumann PJ: Alzheimer's disease care: Costs and potential savings. Health Aff. 1998; 17(6): 206-216.
10. Menzin J, Lang K, Friedman M, et al.: The economic cost of Alzheimer's disease and related dementias to the California Medicaid Program ("Medi-Cal") in 1995. Am J Geriatr Psychiatry. 1999; 7(4): 300-308.
11. Rice DP, Fox PJ, Max W, et al.: The economic burden of Alzheimer's disease care. Health Aff. 1993; 12(2): 164-176.
12. Schumock GT: Economic considerations in the treatment and management of Alzheimer's disease. Am J Health Syst Pharm. 1998; 55(Suppl 2): S17-S21.
13. Max W, Webber P, Fox P: Alzheimer's disease: The unpaid burden of caring. J Aging Health. 1995; 7(2): 179-199.
14. Gutterman EM, Markowitz JS, Lewis B, et al.: Cost of Alzheimer's disease and related dementia in managed-medicare. J Am Geriatr Soc. 1999; 47(9): 1065-1071.
15. Taylor DH, Sloan FA: How much do persons with Alzheimer's disease cost Medicare? J Am Geriatr Soc. 2000; 48(6): 639-646.
16. Brummel-Smith KV: Alzheimer's disease and managed care: How much will it cost? J Am Geriatr Soc. 1998; 46(6): 762-770.
17. McCormick WC, Hardy J, Kukull WA, et al.: Healthcare utilization in costs in managed care patients with Alzheimer's disease during the last few years of life. J Am Geriatr Soc. 2001; 49(9): 1156-1160.
18. Walsh EG, Wu B, Mitchell JB, et al.: Cognitive function and acute care utilization. J Gerontol B Psychol Sci Soc Sci. 2003; 58(1): S38-S49.
19. Charlson ME, Pompei P, Ales KL, et al.: A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987; 40(5): 373-383.
20. Duan N: Smearing estimate: A nonparametric retransformation method. J Am Statistical Assoc. 1983; 78: 605-610.
21. Winblad B, Wimo A: Assessing the societal impact of acetylcholinesterase inhibitor therapies. Alzheimer Dis Assoc Disord. 1999; 13 (Suppl 2): S9-S19.
22. Reisberg B, Doody R, Stoffler A, et al.: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003; 348: 1333-1341.
23. Husereau D, Wolfson C, Shukla VK: Drug Treatments for Alzheimer's Disease: Efficacy, Outcome Measurements and Cost-Effectiveness. Technology Overview no. 4. Ottawa: Canadian Coordinating Office on Health Technology Assessment, 2001.
24. Bloom BS, de Pouvourville N, Straus WL: Cost of illness of Alzheimer's disease: How useful are current estimates? Gerontologist. 2003; 43(2): 158-164.
25. Weiner M, Powe NR, Weller WE, et al.: Alzheimer's disease under managed care: Implications from Medicare utilization and expenditure patterns. J Am Geriatr Soc. 1998; 46(6): 762-770.
26. Fillit H, Hill J: The costs of vascular dementia: a comparison with Alzheimer's disease. J Neurol Sci. 2002; 203-204: 35-39.
27. Taylor DH Jr, Schenkman M, Zhou J, et al.: The relative effect of Alzheimer's disease and related dementias, disability, and comorbidities on cost of care for elderly persons. J Gerontol B Psychol Sci Soc Sci. 2001; 56(5): S285-S293.